- Date 20 Jul 2021
Lonza and CN Bio have entered into a distribution agreement whereby Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in their PhysioMimixTM Single-and Multi-Organ MPS to transform the way human-relevant pre-clinical data is generated. With prequalified cells, customers can avoid having to trial numerous cell types in order to be assured of finding ones that will grow and behave functionally in 3D culture and fast-track their route to generating reliable and robust data.
You might also be interested in these articles
Technology
Answer the call for speakers & start-ups for CW's International Conference
None
Thu 7 Nov 2024
CW (Cambridge Wireless Ltd)
Technology
Celebrating the Cambridge Tech Week Innovation Alley Award Winners
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)
Technology
Optalysys wins the Business Weekly and Cambridge Tech Week Scale-Up Business Plan Competition
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)